On the upside
Honeywell (NYSE: HON) will pay a premium of approximately $603.4 million in cash to purchase Intermec (NYSE: IN).
Geron (Nasdaq: GERN) reported upbeat results from a Phase 2 clinical trial of its essential thrombocythemia treatment imetelstat.
On the downside
A Food and Drug Administration panel recommended that the regulatory agency not approve Zogenix's (NYSE: NXY) moderate to severe pain treatment Zohydro.
Oppenheimer suggested that investors take a cautious approach to Nokia (NYSE: NOK).
Investors locked in profits on Groupon (Nasdaq: GRPN), whose stock price soared last week on rumors that Google (Nasdaq: GOOG) was interested in acquiring the company.
In the broad market, advancing issues outpaced decliners by a margin of nearly 9 to 7 on both the NYSE and on Nasdaq. The Russell 2000 which tracks small cap stocks added 2 points to 824.